Embed Size (px)
Citation preview
USA – CANADA – UK – CHINA – INDIA
Global Anxiety Disorders Market 2015-2019
• The report discusses the following in-depth:
• Market Segmentation by Product
• Market Segmentation by Nature of Transaction
• Demographic Segmentation
• Service Segmentation
• Business Segmentation by Revenue
• Geographical Segmentation by Revenue
For more information on theGlobal Anxiety Disorders Market
2015-2019,please mail us at
USA – CANADA – UK – CHINA – INDIA
Key Trends
TechNavio’s senior analyst says, “Despite the presence of several challenges, the Global Anxiety Disorders market is expected to grow during the forecast period because of some emerging trends. One such trend is increased focus on emerging markets.”
• Anxiety is associated with uneasiness, fearfulness, and tension. Mild anxiety, for example, associated with exams or interviews, is normal and triggers 'fight or flight' response. Anxiety without an unidentifiable cause, which persists even after the stressful condition is over and which is out of proportion of the stressful condition, indicates abnormal anxiety.
• The Global Anxiety Disorders market was valued at US$5.28 billion in 2014 and is expected to experience sluggish growth with a CAGR of 4.02 percent during the forecast period.
• Understanding the key drivers influencing the market
• Understanding the challenges faced by the market
• Activities of various stakeholders involved
• Enabling technologies and the roadmap
• Key focus areas for the vendors
• Major trends that will shape the future of this market
• Vendor landscape and trajectory of the market
• Conclusion
Scope of The Report
A detailed analysis of each market driver, challenge and trend is
available in our report:Global Anxiety Disorders Market 2015-2019
USA – CANADA – UK – CHINA – INDIA
Vendor Landscape
For a full list of vendors view our report,
Global Anxiety Disorders Market 2015-2019
Eli Lilly and Company
GlaxoSmithKline
Pfizer
In the US, the revenue of Cymbalta sales decreased to US$3,960.8 million in 2013 because of generic entry in the US. Cymbalta lost its compound patent plus pediatric exclusivity in the US in December 2013 but still holds data package protection in Japan.
GlaxoSmithKline offers Seroxat/Paxil and Paxil CR for the treatment of anxiety disorders. In Europe, Paxil is marketed under the brand name Seroxat. In October 2014, GlaxoSmithKline and Sumitomo Dainippon Pharma announced their agreement to terminate their co-promotion agreement over Paxil CR.
Pfizer markets a wide range of products for the treatment of anxiety disorders such as Xanax, Xanax XR, Effexor, Effexor XR, Lyrica, Zoloft, and Vistaril.
USA – CANADA – UK – CHINA – INDIA
Market Landscape
• The Global Anxiety Disorders market is expected to grow at a slow rate during the forecast period.
• Factors such as increased patient population and increase in awareness are contributing to the market growth.
• Also, demand for drugs with superior efficacy and safety profiles and reduced side effects are increasing among patients.
USA – CANADA – UK – CHINA – INDIA
Key Buying CriteriaGuest Bloggers
• Authenticity • Delivery • Price• Service Support
Parameter Details
Cost Drugs available at reasonable prices are preferable
EfficacyDrugs with higher efficacy are preferable and have high
demand
Safety Drugs with fewer side effects have high demand
• Growth Forecasts?
• Market Analysis?
• Revenue Forecasts?
• Regional and Country level Analysis?
• Competitive Structure?
• Emerging Trends?
• Vendor Landscape?
• Other?
How would you like to engage with TechNavio?
Global Anxiety Disorders Market 2015-2019
USA – CANADA – UK – CHINA – INDIA
Reports Cover : Market Scenarios, Vendor landscape & Industry Road Maps.Option to Customize Report & Access to Analysts on every Report Purchase.
Option to Customize Reports
Ask an AnalystOr
Inform us by e-mailing
USA – CANADA – UK – CHINA – INDIA
Access the Report
USA – CANADA – UK – CHINA – INDIA
India: An Overview
USA – CANADA – UK – CHINA – INDIA
About Us
USA – CANADA – UK – CHINA – INDIA
Thank You!
North America
Chicago, USA
Phone: +1 630 333 9501
Fax: +1 630 833 2171
Europe
London, United Kingdom
Phone: +44 208 123 1770
Fax: +44 845 280 2825
Asia
Bangalore, India
Phone: +91 934 254 0560
Fax: +91 80 4080 6070
DISCLAIMER
This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of
or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.
Copyright ©2013 Infiniti Research Limited. All Rights Reserved.
Reproduction without written permission is completely forbidden.
NOT FOR FURTHER DISTRIBUTION
